Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Current treatment strategies for newly diagnosed Hodgkin lymphoma

David Straus • 18 Aug 2020
SOHO 2020
Hodgkin Lymphoma Lymphoma Bleomycin Dacarbazine Doxorubicin Vinblastine

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, outlines the current treatment strategies in newly diagnosed Hodgkin lymphoma, and explores the use of radiotherapy in some patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Straus

6:38
IVAC +/- rituximab in R/R B-NHLs: a real-world data review
David Straus • 2 Dec 2020
8:50
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial
David Straus • 2 Dec 2020
2:34
R/R lymphoma: checkpoint blockade and transplantation
David Straus • 18 Aug 2020
3:24
Treatment of bulky stage I/II lymphoma
David Straus • 18 Aug 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals